1092938-92-5

Basic information

• Product Name: 4-Methoxycyclohexene-1-boronic Acid Pinacol Ester
• Synonyms: 4-Methoxycyclohexene-1-boronic Acid Pinacol Ester;2-(4-Methoxycyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;2-(4-methoxycyclohex-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;2-(4-Methoxy-1-cyclohexenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;2-(4-methoxycyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS NO: 1092938-92-5
• Molecular Formula: C₁₃H₂₃BO₃
• Molecular Weight: 256.1462
• Product Categories: Organic boronic acid
• Mol File: 1092938-92-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 263.1±50.0 °C(Predicted)
• Appearance: /
• Density: 0.98±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 4-Methoxycyclohexene-1-boronic Acid Pinacol Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxycyclohexene-1-boronic Acid Pinacol Ester(1092938-92-5)
• EPA Substance Registry System: 4-Methoxycyclohexene-1-boronic Acid Pinacol Ester(1092938-92-5)

Safety Data

• Hazardous Substances Data: 1092938-92-5(Hazardous Substances Data)

Usage

Uses

4-Methoxycyclohexene-1-boronic acid pinacol ester is used in the synthetic preparation of pyrazine compounds as phosphodiesterase 10 inhibitors. These inhibitors are useful in the treatment of various disorders and or diseases such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder and obsessive-compulsive disorder.

Upstream product

• 13482-23-0 4-methoxycyclohexanone 
• 73183-34-3 bis(pinacol)diborane 
• 1092938-89-0 4-methoxycyclohex-1-en-1-yl trifluoromethanesulfonate 

Downstream Products

• 1227067-21-1 1H-benzimidazol-2-yl(4-((3-(4-methoxy-1-cyclohexen-1-yl)-2-pyrazinyl)oxy)phenyl)methanone 
• 1374341-92-0 ethyl 1-{6-[4'-(4-methoxycyclohex-1-en-1-yl)-4-methylbiphenyl-2-yl]pyridin-2-yl}-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1374341-93-1 ethyl 1-{6-[4'-(trans-4-methoxycyclohexyl)-4-methylbiphenyl-2-yl]pyridin-2-yl}-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1374341-94-2 ethyl 1-{6-[4'-(cis-4-methoxycyclohexyl)-4-methylbiphenyl-2-yl]pyridin-2-yl}-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 1374338-77-8 1-{6-[4'-(cis-4-methoxycyclohexyl)-4-methylbiphenyl-2-yl]pyridin-2-yl}-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 
• 1374338-78-9 1-{6-[4'-(4-methoxycyclohex-1-en-1-yl)-4-methylbiphenyl-2-yl]pyridin-2-yl}-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 

Relevant articles and documents

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.